Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook
Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook
Overview
Denmark vaccine maker's Q3 revenue was flat yr/yr at DKK 1,805 mln
Q3 EBITDA margin rose to 34.4%, up from 29% last year
Company completed DKK 500 mln share buyback, launched new program up to DKK 750 mln
Outlook
Company maintains full-year 2026 revenue guidance of about DKK 6,100 mln
Bavarian Nordic expects 2026 EBITDA margin to reach about 32%
Company says outlook reflects increased investment levels in Q4
Result Drivers
TRAVEL HEALTH GROWTH - Co said Q3 Travel Health revenue rose 22%, driven by strong RabAvert/Rabipur sales and Vimkunya launch
PRODUCT AND MARKET MIX - Co said higher gross margin was due to strong topline and advantageous product and market mix
PUBLIC PREPAREDNESS STABLE - Public Preparedness revenue was in line with expectations, supporting overall performance
Company press release: ID:nGNE1hmS3
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue |
| DKK 1.81 bln |
|
Q3 EBITDA |
| DKK 621 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Bavarian Nordic A/S is DKK280.00, about 16.8% above its November 12 closing price of DKK239.80
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 21 three months ago
Reuters Recommended Reads
Nov 10 - Lundbeck hikes annual forecasts as migraine drug powers earnings beat
Nov 10 - Denmark's Lundbeck posts higher Q3 profit, raises FY revenue and EBITDA guidance
Nov 12 - Zealand Pharma seeks partners for rare-disease assets as obesity focus grows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Bavarian Nordic A/S
See all newsBavarian Nordic beats Q3 revenue expectations on travel health strength (updated)
Bavarian Nordic beats Q3 revenue expectations
Brief: Bavarian Nordic Launches Next Tranche Of Share Buy-Back Program
Brief: Bavarian Nordic CFO Henrik Juuel To Step Down
Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook